Literature DB >> 17229503

Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.

C Olive1, K Schulze, H Kuo Sun, T Ebensen, A Horváth, I Toth, C A Guzman.   

Abstract

We investigated the efficacy of a synthetic Streptococcus pyogenes vaccine targeting two virulence factors using the Lipid Core Peptide (LCP) delivery system. BALB/c mice were immunised intranasally with LCPs containing peptides encompassing T-cell and B-cell epitopes of the conserved C-repeat region of the M protein (J8) or the fibronectin-binding repeats region (FNBR) of SfbI, or a combination formulation containing peptides representing both antigens. LCPs were co-administered with the TLR2/6 agonist MALP-2 as mucosal adjuvant. Humoral and cellular immune responses stimulated at systemic and mucosal levels were strongest in mice immunised with the dual antigen formulation. Mice were completely protected following a respiratory challenge with a lethal dose of a heterologous S. pyogenes strain, whereas there was 70% and 90% survival in mice immunised with LCP-J8 and LCP-FNBR, respectively. This is the first report demonstrating the elicitation of better protective immunity by a dual antigen component S. pyogenes vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17229503     DOI: 10.1016/j.vaccine.2006.11.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

2.  The FasX Small Regulatory RNA Negatively Regulates the Expression of Two Fibronectin-Binding Proteins in Group A Streptococcus.

Authors:  Jessica L Danger; Nishanth Makthal; Muthiah Kumaraswami; Paul Sumby
Journal:  J Bacteriol       Date:  2015-09-21       Impact factor: 3.490

Review 3.  Cutting edge issues in rheumatic fever.

Authors:  Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 4.  Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.

Authors:  Matthew Black; Amanda Trent; Matthew Tirrell; Colleen Olive
Journal:  Expert Rev Vaccines       Date:  2010-02       Impact factor: 5.217

5.  Genes, autoimmunity and pathogenesis of rheumatic heart disease.

Authors:  L Guilherme; K F Köhler; E Postol; J Kalil
Journal:  Ann Pediatr Cardiol       Date:  2011-01

Review 6.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

Review 7.  Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.

Authors:  Armira Azuar; Wanli Jin; Saori Mukaida; Waleed M Hussein; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2019-07-01

8.  StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice.

Authors:  Edilberto Postol; Raquel Alencar; Fabio T Higa; Samar Freschi de Barros; Lea M F Demarchi; Jorge Kalil; Luiza Guilherme
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 9.  Towards developing a vaccine for rheumatic heart disease.

Authors:  Geethanjali Devadoss Gandhi; Navaneethakrishnan Krishnamoorthy; Ussama M Abdel Motal; Magdi Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2017-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.